Sector News

Teva looks to sell generics in China through JV: Bloomberg

November 6, 2017
Life sciences

As the world’s largest generics maker, Teva still doesn’t have much of a presence in China, even though it is a country relies heavily on generics. The Israeli company is looking to remedy that by reportedly forming a joint venture with local company Guangzhou Pharma, according to Bloomberg.

The intel came from a Bloomberg interview with Li Chuyuan, the chairman of the Chinese firm which is known for some traditional Chinese medicine and a Viagra copycat. He also said his company is awaiting Chinese approvals for some Teva drugs.

In a statement quoted by Bloomberg, Teva said it “has no agreement with any local partner to form a JV in China,” but went short of denying such a possibility or whether it’s in talks with Guangzhou Pharma.

Teva had made some inroads in China more than a decade ago with a $7.4 billion Ivax acquisition deal in which it gained 50% of the shares in Kunming Baker Norton Pharma, a joint venture between China’s Kunming Pharma and Ivax. The company’s amoxicillin is one of the best-selling antibiotics in China. But then in 2015, Kunming Pharma bought back 49% of the shares, leaving only 1% for Teva.

Teva has an API plant in China—which was dealt a warning letter from the U.S. FDA in April—and is selling drugs through a distribution agreement with a local company.

Different market analyses have put different numbers on China’s generics market size. A report (PDF) by the U.S. Department of Commerce put China’s generics sales in 2016 at $68 million, accounting for 64% of the country’s total drug sales, and said that it is expected to reach $80 million this year, surpassing the U.S. Another report by Fitch Ratings said the market share occupied by copycat drugs in China was 85%.

Teva has been reeling from a host of issues from growing competition, slower-than-expected launches, as well as the pricing pressures that has taken a toll on the entire generics industry. The company just slashed its guidance again to $22.2 billion ~ $22.3 billion from $22.8 billion ~ $23.2 billion, its third downgrade in the last four quarters.

Whether China embodies growth for Teva will be a question for new CEO Kåre Schultz.

In its 2016 annual filings to the SEC, the Israeli generics giant said, “Over time and with the right opportunities, we intend to expand our presence in markets such as China and Brazil.”

China represents a mixed opportunity, though. On the one hand, its regulatory environment and culture make it difficult to navigate, so, many foreign biopharmas have formed partnerships with local companies to help derisk their efforts there–where Guangzhou Pharma could be of assistance to Teva. Besides, Teva will also face some of the same obstacles it has already stumbled upon elsewhere in the world; the government is also pressing for lower drug prices, and given the country’s high reliance on generics, competition is almost guaranteed.

But as the country’s population ages, and in order to keep drug prices in check, China will continue to welcome generics where applicable. As China is pushing for a thorough generic bioequivalence evaluation to ensure quality of copycat drugs, many noncompliant manufacturers that have sustained mainly on low prices will be eliminated, giving internationally renowned players like Teva an opportunity. At the same time, local drug regulator is also rolling out a series of policy changes aimed at speeding drug approvals and at opening the market further to foreign drugs.

By Angus Liu

Source: Fierce Pharma

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend